Journal article

Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology.

David Castle, Francesca Beilharz, Katharine A Phillips, Vlasios Brakoulias, Lynne M Drummond, Eric Hollander, Konstantinos Ioannidis, Stefano Pallanti, Samuel R Chamberlain, Susan L Rossell, David Veale, Sabine Wilhelm, Michael Van Ameringen, Bernardo Dell'Osso, Jose M Menchon, Naomi A Fineberg

International Clinical Psychopharmacology | Published : 2021

Abstract

Body dysmorphic disorder (BDD) is characterized by a preoccupation with a perceived appearance flaw or flaws that are not observable to others. BDD is associated with distress and impairment of functioning. Psychiatric comorbidities, including depression, social anxiety, and obsessive-compulsive disorder are common and impact treatment. Treatment should encompass psychoeducation, particularly addressing the dangers associated with cosmetic procedures, and may require high doses of selective serotonin reuptake inhibitors* (SSRI*) and protracted periods to establish full benefit. If there is an inadequate response to SSRIs, various adjunctive medications can be employed including atypical anti..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institute for Health Research (Department of Health)


Citation metrics